Runzi Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Runzi Sun has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Binfeng Lu
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
55 shared publications - Jingting Jiang
Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Jiangsu Changzhou, China
54 shared publications - David Shihong Gao
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
38 shared publications - Andrew Ni
Department of Neurology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
37 shared publications - Ella Li
Anwita Biosciences Inc, San Carlos, California
36 shared publications - Fan Ye
Anwita Biosciences Inc, San Carlos, California
36 shared publications
Latest Publications
- Open Access
- 25 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (34) , eadd7399
Amphiregulin couples IL1RL1 + regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity
Regulatory T (T reg ) cells and cancer-associated fibroblasts (CAFs) jointly promote tumor immune tolerance and tumorigenesis. The molecular apparatus that drives T reg cell and CAF coordination in the tumor microenvironment (TME) remains elusive. Interleukin 33 (IL-33) has been shown to enhance fibrosis and IL1RL1 + T reg cell accumulation during tumorigenesis and tissue repair. We demonstrated that IL1RL1 signaling in T reg cells greatly dampened the antitumor activity of both IL-33 and PD-1 blockade. Whole tumor single-cell RNA sequencing (scRNA-seq) analysis and blockade experiments revealed that the amphiregulin (AREG)–epidermal growth factor receptor (EGFR) axis mediated cross-talk between IL1RL1 + T reg cells and CAFs. We further demonstrated that the AREG/EGFR axis enables T reg cells to promote a profibrotic and immunosuppressive functional state of CAFs. Moreover, AREG mAbs and IL-33 concertedly inhibited tumor growth. Our study reveals a previously unidentified AREG/EGFR-mediated T reg /CAF coupling that controls the bifurcation of fibroblast functional states and is a critical barrier for cancer immunotherapy.
- 25 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (34) , eadd7399
Open AccessAmphiregulin couples IL1RL1 + regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity
Regulatory T (T reg ) cells and cancer-associated fibroblasts (CAFs) jointly promote tumor immune tolerance and tumorigenesis. The molecular apparatus that drives T reg cell and CAF coordination in the tumor microenvironment (TME) remains elusive. Interleukin 33 (IL-33) has been shown to enhance fibrosis and IL1RL1 + T reg cell accumulation during tumorigenesis and tissue repair. We demonstrated that IL1RL1 signaling in T reg cells greatly dampened the antitumor activity of both IL-33 and PD-1 blockade. Whole tumor single-cell RNA sequencing (scRNA-seq) analysis and blockade experiments revealed that the amphiregulin (AREG)–epidermal growth factor receptor (EGFR) axis mediated cross-talk between IL1RL1 + T reg cells and CAFs. We further demonstrated that the AREG/EGFR axis enables T reg cells to promote a profibrotic and immunosuppressive functional state of CAFs. Moreover, AREG mAbs and IL-33 concertedly inhibited tumor growth. Our study reveals a previously unidentified AREG/EGFR-mediated T reg /CAF coupling that controls the bifurcation of fibroblast functional states and is a critical barrier for cancer immunotherapy.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Supplementary Figure 1. Distribution of CD4+ T cell subsets.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Supplementary Figure 1. Distribution of CD4+ T cell subsets.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21-anti-HSA and anti-PD-1 mAb administration drives phenotypic polarization and clonal expansion of Treg cells. A, UMAP showing Treg cell subsets, including pre-eTreg cells, eTreg cells, and cycling Treg cells. B, Contour heat map of Treg cell subsets split by different treatment conditions. C, Bar plot of Treg cell subsets under different treatment conditions. D, Heat map showing expression of selected DEGs in Treg cells. E, TCR clonal expansion fractions and average clonal sizes of total Treg cells under different treatment conditions.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21-anti-HSA and anti-PD-1 mAb administration drives phenotypic polarization and clonal expansion of Treg cells. A, UMAP showing Treg cell subsets, including pre-eTreg cells, eTreg cells, and cycling Treg cells. B, Contour heat map of Treg cell subsets split by different treatment conditions. C, Bar plot of Treg cell subsets under different treatment conditions. D, Heat map showing expression of selected DEGs in Treg cells. E, TCR clonal expansion fractions and average clonal sizes of total Treg cells under different treatment conditions.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Supplementary Figure 2. FTY720 injection did not affect on anti-PD-1 anti-tumor effect.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Supplementary Figure 2. FTY720 injection did not affect on anti-PD-1 anti-tumor effect.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Supplementary Figure 3. IL21-anti-HSA/anti-PD-1 leads to altered immune cell populations in the tumor microenvironment.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Supplementary Figure 3. IL21-anti-HSA/anti-PD-1 leads to altered immune cell populations in the tumor microenvironment.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21-anti-HSA and anti-PD-1 mAb administration drives phenotypic polarization and clonal expansion of Treg cells. A, UMAP showing Treg cell subsets, including pre-eTreg cells, eTreg cells, and cycling Treg cells. B, Contour heat map of Treg cell subsets split by different treatment conditions. C, Bar plot of Treg cell subsets under different treatment conditions. D, Heat map showing expression of selected DEGs in Treg cells. E, TCR clonal expansion fractions and average clonal sizes of total Treg cells under different treatment conditions.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21-anti-HSA and anti-PD-1 mAb administration drives phenotypic polarization and clonal expansion of Treg cells. A, UMAP showing Treg cell subsets, including pre-eTreg cells, eTreg cells, and cycling Treg cells. B, Contour heat map of Treg cell subsets split by different treatment conditions. C, Bar plot of Treg cell subsets under different treatment conditions. D, Heat map showing expression of selected DEGs in Treg cells. E, TCR clonal expansion fractions and average clonal sizes of total Treg cells under different treatment conditions.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21-anti-HSA/PD-1 mAbs combination therapy alters T-cell function and increases T-cell clonal expansion. A, UMAP showing CD8+ T-cell subsets, including exhausted, cycling, stem-like, effector, and IFN-induced. B, Pseudotime plot of CD8+ T-cell subsets constructed by Monocle3. C, Contour heat map of CD8+ T-cell subsets split by different treatment conditions. D, Bar plots of CD8+ T-cell subsets under different treatment conditions. E, Heat map showing selected DEGs on exhausted CD8+ T cells in different treatment conditions. F, Bar plots showing TCR clonal expansion fractions and average clonal sizes of total CD8+ T cells under different treatment conditions. G, Dot plot showing expression of selected genes associated with the cell cycle on different CD8+ T-cell subsets under different treatment conditions. H, Dot plot showing expression of selected genes associated with glycolysis on different CD8+ T-cell subsets. I, Heat map showing expression of selected DEGs in CD4+ T cells under different treatment conditions. J, TCR clonal expansion fractions and average clonal sizes of CD4+ T cells under different treatment conditions.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21-anti-HSA/PD-1 mAbs combination therapy alters T-cell function and increases T-cell clonal expansion. A, UMAP showing CD8+ T-cell subsets, including exhausted, cycling, stem-like, effector, and IFN-induced. B, Pseudotime plot of CD8+ T-cell subsets constructed by Monocle3. C, Contour heat map of CD8+ T-cell subsets split by different treatment conditions. D, Bar plots of CD8+ T-cell subsets under different treatment conditions. E, Heat map showing selected DEGs on exhausted CD8+ T cells in different treatment conditions. F, Bar plots showing TCR clonal expansion fractions and average clonal sizes of total CD8+ T cells under different treatment conditions. G, Dot plot showing expression of selected genes associated with the cell cycle on different CD8+ T-cell subsets under different treatment conditions. H, Dot plot showing expression of selected genes associated with glycolysis on different CD8+ T-cell subsets. I, Heat map showing expression of selected DEGs in CD4+ T cells under different treatment conditions. J, TCR clonal expansion fractions and average clonal sizes of CD4+ T cells under different treatment conditions.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Data from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
T cell–stimulating cytokines and immune checkpoint inhibitors (ICI) are an ideal combination for increasing response rates of cancer immunotherapy. However, the results of clinical trials have not been satisfying. It is important to understand the mechanism of synergy between these two therapeutic modalities. Here, through integrated analysis of multiple single-cell RNA sequencing (scRNA-seq) datasets of human tumor-infiltrating immune cells, we demonstrate that IL21 is produced by tumor-associated T follicular helper cells and hyperactivated/exhausted CXCL13+CD4+ T cells in the human tumor microenvironment (TME). In the mouse model, the hyperactivated/exhausted CD4+ T cell–derived IL21 enhances the helper function of CD4+ T cells that boost CD8+ T cell–mediated immune responses during PD-1 blockade immunotherapy. In addition, we demonstrated that IL21’s antitumor activity did not require T-cell trafficking. Using scRNA-seq analysis of the whole tumor-infiltrating immune cells, we demonstrated that IL21 treatment in combination with anti-PD-1 blockade synergistically drives tumor antigen–specific CD8+ T cells to undergo clonal expansion and differentiate toward the hyperactive/exhausted functional state in the TME. In addition, IL21 treatment and anti-PD-1 blockade synergistically promote dendritic cell (DC) activation and maturation to mature DC as well as monocyte to type 1 macrophage (M1) differentiation in the TME. Furthermore, the combined treatment reprograms the immune cellular network by reshaping cell-cell communication in the TME. Our study establishes unique mechanisms of synergy between IL21 and PD-1–based ICI in the TME through the coordinated promotion of type 1 immune responses.Significance:This study reveals how cytokine and checkpoint inhibitor therapy can be combined to increase the efficacy of cancer immunotherapy.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
T cell–stimulating cytokines and immune checkpoint inhibitors (ICI) are an ideal combination for increasing response rates of cancer immunotherapy. However, the results of clinical trials have not been satisfying. It is important to understand the mechanism of synergy between these two therapeutic modalities. Here, through integrated analysis of multiple single-cell RNA sequencing (scRNA-seq) datasets of human tumor-infiltrating immune cells, we demonstrate that IL21 is produced by tumor-associated T follicular helper cells and hyperactivated/exhausted CXCL13+CD4+ T cells in the human tumor microenvironment (TME). In the mouse model, the hyperactivated/exhausted CD4+ T cell–derived IL21 enhances the helper function of CD4+ T cells that boost CD8+ T cell–mediated immune responses during PD-1 blockade immunotherapy. In addition, we demonstrated that IL21’s antitumor activity did not require T-cell trafficking. Using scRNA-seq analysis of the whole tumor-infiltrating immune cells, we demonstrated that IL21 treatment in combination with anti-PD-1 blockade synergistically drives tumor antigen–specific CD8+ T cells to undergo clonal expansion and differentiate toward the hyperactive/exhausted functional state in the TME. In addition, IL21 treatment and anti-PD-1 blockade synergistically promote dendritic cell (DC) activation and maturation to mature DC as well as monocyte to type 1 macrophage (M1) differentiation in the TME. Furthermore, the combined treatment reprograms the immune cellular network by reshaping cell-cell communication in the TME. Our study establishes unique mechanisms of synergy between IL21 and PD-1–based ICI in the TME through the coordinated promotion of type 1 immune responses.Significance:This study reveals how cytokine and checkpoint inhibitor therapy can be combined to increase the efficacy of cancer immunotherapy.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21 is produced by both CXCR5+ Tfh cells and hyperactivated/exhausted CD4+ T cells in the TME. A and B, Dot plots and UMAPs showing the expression of selected genes in different CD4+ T-cell subsets in integrated human cancer tissues. C and D, Dot plots and UMAPs showing the expression of selected genes in different CD4+ T-cell subsets in mouse MC38 colon adenocarcinoma tumors. E, UMAP plot showing imputed expression of selected genes constructed by ArchR.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
IL21 is produced by both CXCR5+ Tfh cells and hyperactivated/exhausted CD4+ T cells in the TME. A and B, Dot plots and UMAPs showing the expression of selected genes in different CD4+ T-cell subsets in integrated human cancer tissues. C and D, Dot plots and UMAPs showing the expression of selected genes in different CD4+ T-cell subsets in mouse MC38 colon adenocarcinoma tumors. E, UMAP plot showing imputed expression of selected genes constructed by ArchR.
- Open Access
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
FIGURE 6 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Combination therapy enhances DC activation and maturation. A, UMAP showing DC subsets, including mDC, cDC1, cDC2, pDC. B, DC subset proportions bar graph. C–E, Heat map showing the expression of selected DEGs in cDC1, cDC2, mDC cells under different treatment conditions. F, Dot plot showing expression of selected genes on different DC subsets under different treatment conditions. G, Dot plot showing expression of Il21r on different DC subsets under different treatment conditions.
- 4 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 6 from Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
Combination therapy enhances DC activation and maturation. A, UMAP showing DC subsets, including mDC, cDC1, cDC2, pDC. B, DC subset proportions bar graph. C–E, Heat map showing the expression of selected DEGs in cDC1, cDC2, mDC cells under different treatment conditions. F, Dot plot showing expression of selected genes on different DC subsets under different treatment conditions. G, Dot plot showing expression of Il21r on different DC subsets under different treatment conditions.